semaglutide shortage end The Ozempic Is Over FDA says that the GLP-1

Behavioral interventions such as motivational interviewing and encouraging physical activity lead to additional weight loss when combined with dietary changes

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that has revolutionized the management of type 2 diabetes and obesity

Glucose stimulates insulin release from pancreatic cells in a biphasic manner

The results of the phase 3 trial of the weight loss drug have been released

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses the top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs.

This design yields a ~1-week half-life while preserving high affinity and selectivity for GLP-1R